載入中
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
前收盤價
US$1.28
−US$0.05 · -3.76%
盤中時間採用ET。市場資料可能有所延遲。
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
日內區間
目前US$1.28
52週區間
目前US$1.28
盤中時間採用ET。市場資料可能有所延遲。
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
日內區間
目前US$1.28
52週區間
目前US$1.28
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 112.3萬 USD | 4.3萬 USD | — | — | — |
| 銷貨成本 | 32.7萬 USD | — | — | — | — |
| 毛利 | 79.6萬 USD | 4.3萬 USD | — | — | — |
| 研究與開發 | 626.9萬 USD | 602.5萬 USD | 566.7萬 USD | 430.1萬 USD | 303.9萬 USD |
| 銷售、一般及管理費用 | 703.7萬 USD | 498.8萬 USD | 572.9萬 USD | 564.9萬 USD | 263.2萬 USD |
| 營業費用 | 1330.6萬 USD | 1101.3萬 USD | 1139.6萬 USD | 995萬 USD | 567.1萬 USD |
| 利息收入 | 42.7萬 USD | 38.4萬 USD | — | 5.7萬 USD | 7萬 USD |
| 利息支出 | — | — | 10.8萬 USD | 5.7萬 USD | 90.4萬 USD |
| 折舊和攤銷 | 2000 USD | — | 6000 USD | 6000 USD | 9000 USD |
| 營業利益 | −1251萬 USD | −1097萬 USD | −1139.6萬 USD | −995萬 USD | −567.1萬 USD |
| 淨利 | −1116.8萬 USD | −881.4萬 USD | −1023.2萬 USD | −988.9萬 USD | −632.4萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
